Blandt patienter, som initielt ikke fik reperfusion, reducerede fondaparinux incidensen af død/ re- MI signifikant efter 30 dage fra 15% for kontrolgruppen til 12. 1% for fondaparinux- gruppen (hazard rate 0, 79; 95% CI 0, 65 - 097; p = 0, 023).
Among patients initially not reperfused, the incidence of death/ re-MI at Day 30 was significantly reduced from 15% for the control group to 12.1% for the fondaparinux group (hazard ratio 0.79, 95% CI, 0.65; 0.97, p = 0.023).